STAT3 and rheumatoid arthritis: Evidence demonstrates that tofacitinib, a pan-Janus kinase (JAK) inhibitor, is the only FDA-approved drug for RA treatment that downregulated STAT3 signaling mainly by inhibiting JAK expression (Miklossy et al., 2013).